Exozymes Inc. ( (EXOZ) ) has released its Q3 earnings. Here is a breakdown of the information Exozymes Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Exozymes Inc., a synthetic biology company based in Nevada, focuses on developing a unique platform for scalable exploration of natural molecules, operating primarily in the biotechnology sector. The latest earnings report for the quarter ending September 30, 2025, reveals significant financial challenges for Exozymes Inc. The company reported a net loss of $2.29 million for the quarter, with a total net loss of $6.5 million for the first nine months of 2025, compared to a $4.03 million loss in the same period last year. Despite the financial losses, Exozymes Inc. has been actively involved in strategic partnerships and grant-funded projects, including a $3 million share of a $9.2 million grant from the U.S. National Science Foundation. The company also issued stock options and warrants as part of its equity incentive plans, indicating efforts to motivate and retain talent. Looking ahead, Exozymes Inc. faces substantial doubt about its ability to continue as a going concern, primarily due to its pre-revenue status and anticipated funding shortfalls. Management is focused on securing additional financial support and exploring potential revenue-generating opportunities to sustain operations.